Drug Profile
xl 101
Alternative Names: PAS-SLMA; xl-101Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator XL-protein GmbH
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Metabolic disorders
Highest Development Phases
- No development reported Metabolic disorders
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for preclinical development in Metabolic-disorders in Germany
- 09 Aug 2016 xl 101 is available for licensing as of 09 Aug 2016. http://www.xl-protein.com/
- 09 Aug 2016 Preclinical trials in Metabolic disorders in Germany (unspecified route)